Temporary bypass device aims to protect surgical connections in colorectal cancer
NCT ID NCT05632744
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This trial tests a temporary device called CG-100 that is placed inside the intestine during colorectal cancer surgery. The device is designed to protect the surgical connection while it heals, potentially reducing leaks and other complications. The study includes adults aged 22 to 75 who have been diagnosed with colorectal cancer and are scheduled for surgery. The main goal is to check whether the device is safe by monitoring for serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- CG-100 Intraluminal Bypass Device
- What this could lead to
- If safe and effective, this device could help protect the surgical connection during colorectal cancer surgery, potentially reducing complications and improving recovery.
- What could go wrong
- This is a very small early-stage safety study with only 7 participants, so results may not apply to all patients. The device itself carries risks such as infection or device-related injury.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
7 people
The number who actually took part.
- Started
-
Mar 2023
- Finished
-
Apr 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria (pre-operative): 1. Willing to comply with protocol-specified follow-up evaluations 2. 22-75 (inclusive) years of age at screening 3. Diagnosed with colorectal cancer 4. Has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Soroka Medical Center
Rehovot, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to why some cancer treatments work better
- Burning the edges: a new way to stop colon polyps from coming back
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?
- A 2.2 mm scope could spot cancerous tissue in minutes, not days
- The gatekeepers of tumors: scientists probe how blood vessels let immune cells in
- New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers